Given its extensive impact, targeting TRIM44 emerges as a promising therapeutic strategy in MM, offering potential solutions to overcome resistance to existing treatments and providing new avenues for addressing MM. The gene discussed is TRIM44; the disease is Miyoshi myopathy.